MarketCap
Sol-Gel Technologies Ltd. SLGL
$ 61.62
-2.21%
Facebook
X
Telegram
Sol-Gel Technologies Ltd. DSO Ratio | SLGL
Annual DSO Ratio Sol-Gel Technologies Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.4 | 62.8 | 967 | 983 | 88.8 | 131 | 32.8 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 983 | 32.8 | 331 |
Quarterly DSO Ratio Sol-Gel Technologies Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.3 | 36 | 38.2 | 54 | 75.8 | 169 | - | - | - | - | - | - | 47 | - | - | - | 47.2 | - | - | - | 45.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 169 | 28.3 | 60.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M |  USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
107 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
258 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
54.9 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
134 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
50.7 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Theratechnologies
THTX
|
82.9 | - | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
43.4 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
636 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
57.8 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.3 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
INmune Bio
INMB
|
19.9 K | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
58 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
62 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
Longeveron
LGVN
|
28.6 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
211 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 1.63 | 1.87 % | $ 2.68 M |  Israel |
 |
Mesoblast Limited
MESO
|
0.00568 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.33 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
114 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
30.9 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
365 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Merck & Co.
MRK
|
61.9 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
Curis
CRIS
|
64.7 | $ 0.88 | 3.67 % | $ 11.6 M | USA |